Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.62 |
| ▸ | BTK | Q06187 | 12/20 | 0.62 |
| ▸ | LCK | P06239 | 2/20 | 0.57 |
| ▸ | LYN | P07948 | 1/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.56 |
| ▸ | ABL1 | P00519 | 6/20 | 0.56 |
| ▸ | HCK | P08631 | 6/20 | 0.56 |
| ▸ | SRC | P12931 | 6/20 | 0.56 |
| ▸ | KDR | P35968 | 6/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.56 |
| ▸ | MTOR | P42345 | 6/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.56 |
| ▸ | EPHB4 | P54760 | 6/20 | 0.56 |
| ▸ | PRKDC | P78527 | 6/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 6/20 | 0.56 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.52 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.52 |
| ▸ | ITK | Q08881 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22230754 | 1.00 | EGFR (0.62) | EGFRBTKLCKLYNPIK3CD | |
| SCHEMBL28749514 | 1.00 | EGFR (0.62) | EGFRBTKLCKLYNPIK3CD | |
| SCHEMBL22243278 | 1.00 | EGFR (0.62) | EGFRBTKLCKLYNPIK3CD | |
| SCHEMBL30381480 | 1.00 | EGFR (0.62) | EGFRBTKLCKLYNPIK3CD | |
| SCHEMBL22243272 | 1.00 | EGFR (0.62) | EGFRBTKLCKLYNPIK3CD | |
| SCHEMBL22230567 | 1.00 | EGFR (0.62) | EGFRBTKLCKLYNPIK3CD | |
| SCHEMBL22230752 | 1.00 | EGFR (0.62) | EGFRBTKLCKLYNPIK3CD | |
| SCHEMBL22230469 | 0.95 | EGFR (0.61) | EGFRBTKLCKLYNPIK3CD | |
| SCHEMBL22230465 | 0.95 | EGFR (0.61) | EGFRBTKLCKLYNPIK3CD | |
| SCHEMBL28749523 | 0.95 | EGFR (0.61) | EGFRBTKLCKLYNPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384786-B2 | Cyclic molecules as Bruton's tyrosine kinase inhibitor | MINGHUI PHARMACEUTICAL SHANGHAI LTD (CN) | 2025-08-12 | — | — | US | disclosed |
| US-20220081445-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR | MINGHUI PHARMACEUTICAL SHANGHAI LTD (CN) | 2022-03-17 | — | — | US | disclosed |
| CN-113710671-A | Cyclic molecules as inhibitors of bruton's tyrosine kinase | 明慧医药（上海）有限公司 | 2021-11-26 | — | — | CN | disclosed |
| EP-3912980-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR | Minghui Pharmaceutical (Shanghai) Limited (CN) | 2021-11-24 | — | — | EP | disclosed |
| CN-111454268-A | Cyclic molecules as inhibitors of bruton's tyrosine kinase | 明慧医药（上海）有限公司 | 2020-07-28 | — | — | CN | disclosed |
| WO-2020147798-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR | 明慧医药（上海）有限公司 | 2020-07-23 | — | — | WO | disclosed |
| WO-2020147798-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR | 明慧医药（上海）有限公司 | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384786-B2 | Cyclic molecules as Bruton's tyrosine kinase inhibitor | ABL1, BTK, LYN | EGFR 418/4885BTK 2/4885LCK 7/4885 |
| US-20220081445-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR | ABL1, BTK, LYN | EGFR 418/4885BTK 2/4885LCK 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.